Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Overview
Neuronetics Inc. (NASDAQ: STIM) is a commercial stage medical technology company that focuses on designing, developing and marketing innovative, noninvasive treatments for mental health and neurohealth disorders. At the heart of its portfolio is the NeuroStar Advanced Therapy System, a revolutionary transcranial magnetic stimulation (TMS) platform that utilizes MRI-strength magnetic field pulses to stimulate targeted regions in the brain. This technology is engineered to serve patients with major depressive disorder (MDD) and other psychiatric conditions, particularly for those who have not experienced satisfactory results with traditional pharmaceutical treatments.
Core Technology and Treatment Modality
Neuronetics has established its reputation by pioneering non-drug, noninvasive therapeutic solutions that redefine patient care in the mental health space. The NeuroStar Advanced Therapy System, cleared by the FDA, is designed to generate pulsed magnetic fields to induce controlled electrical currents in focus areas of the brain. This precise approach not only offers an alternative to systemic medications but also addresses the limitations of conventional treatment methods. The company’s emphasis on robust clinical data and the world’s largest depression outcomes registry reinforces its position as an authority in TMS therapy.
Business Model and Operational Focus
The primary revenue streams for Neuronetics are derived from sales of its NeuroStar system and the associated treatment sessions delivered in a clinical setting. Additionally, the company supports a network of treatment centers that provide these services, thereby integrating technology with operational excellence in patient care. By providing comprehensive clinical training and standardizing best practices through initiatives like its Better Me Provider program, Neuronetics ensures consistent treatment quality. Its business strategy is underpinned by a commitment to continuously engage with payors, healthcare providers and policy makers to expand access to TMS therapy.
Market Position and Competitive Differentiation
Neuronetics occupies a distinct niche in the growing field of neurostimulation devices. Its status as the first company to obtain FDA clearance for a noninvasive TMS device specifically indicated for patients who have not benefited from previous antidepressant medications sets it apart in a competitive market. The company’s dedication to research-driven innovation, combined with its extensive clinical adoption, reinforces its credibility among medical professionals and investors alike. Furthermore, recent strategic mergers have enhanced its operational scale, creating a vertically integrated organization that fosters consistent delivery of standardized best practices across treatment sites.
Clinical Impact and Research Excellence
At the core of Neuronetics’ approach is a commitment to improving patient outcomes. Its NeuroStar Advanced Therapy System has been validated by a significant clinical data set, establishing strong response and remission rates among patients with MDD. The system is also cleared for use in adolescent populations, addressing the critical need for early intervention in mental health care. Neuronetics continues to invest in research and development to assess the full spectrum of benefits associated with TMS therapy, thereby deepening the clinical understanding of treatment efficacy and safety.
Industry Expertise and Authoritativeness
With a dedicated team specialized in health policy advocacy and clinical education, Neuronetics bridges the gap between innovative technology and evidence-based mental health care. The firm’s ability to collaborate with both commercial and government payors to expand insurance coverage for TMS treatments showcases its expertise and strategic foresight. Its work is consistently informed by high-quality clinical research and real-world evidence, making it a trusted source of innovative mental health solutions.
Summary
In summary, Neuronetics stands out in the medical device industry by combining cutting-edge TMS technology with a patient-centric approach to mental health care. Its NeuroStar Advanced Therapy System offers a noninvasive, clinical alternative for those with depression and anxiety, backed by extensive clinical validation. Through its integrated network of treatment centers, robust clinical data and strategic collaborations, Neuronetics reinforces its authority in the neurostimulation space and continues to shape the landscape of mental health treatment.
Neuronetics has partnered with River Region Psychiatry Associates to supply its NeuroStar® Advanced Therapy for mental health, enhancing access to non-drug treatments for depression. The initial system deployment will be in Pelham/Helena, Alabama, with plans for broader distribution across RRPA's clinics. NeuroStar, a non-invasive treatment utilizing transcranial magnetic stimulation (TMS), has successfully delivered over 4 million treatments, showing an 83% response rate and a 62% remission rate. This collaboration aims to meet rising depression cases effectively.
MALVERN, Pa., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Neuronetics, a medical technology company, will release its third quarter financial results on November 9, 2021, before market open. A conference call to discuss these results is scheduled for 8:30 a.m. ET that day, available via webcast on ir.neuronetics.com. Participants can dial in using (877) 472-8990 for U.S. callers or +1 (629) 228-0778 for international callers, referencing code 3891687. The call will be recorded and available for replay for 60 days. Neuronetics focuses on products that enhance the quality of life for neurohealth patients.
Neuronetics, Inc. (NASDAQ: STIM) announced preliminary third-quarter revenue of approximately $13.8 million, falling short of previous guidance of $15.0 million to $16.0 million. The company now expects full-year revenue between $53.3 million and $54.3 million. The lower revenue was attributed to a new sales team's delayed productivity due to extended sales cycles linked to the ongoing Covid-19 situation. Despite this, the company is making progress on strategic initiatives, including a successful NeuroStar Summit and ongoing discussions with the FDA for potential label expansion.
Neuronetics (NASDAQ: STIM) reported preliminary revenues for Q3 2021, expecting approximately $13.8 million, lower than previously estimated guidance of $15.0 million to $16.0 million. Full-year revenue is forecasted to be between $53.3 million and $54.3 million. CEO Keith J. Sullivan attributed the shortfall to the new sales team's productivity challenges amid extended sales cycles influenced by the Covid-19 pandemic. Despite this, the company made progress on strategic initiatives, including successful marketing campaigns and productive discussions with the FDA regarding potential label expansions.
Neuronetics, Inc. (NASDAQ: STIM) has entered an exclusive five-year commercial agreement with Success TMS, which will utilize Neuronetics’ NeuroStar Advanced Therapy exclusively to treat patients with treatment-resistant major depressive disorder (MDD). Additionally, Neuronetics has made a strategic investment of $10 million to support Success TMS's growth. Success TMS aims to triple its size in the next two years, having provided over 250,000 treatments across 30 sites in six states. This partnership emphasizes the commitment to improving patient access to non-drug therapies for neurohealth disorders.
Neuronetics, a medical technology company focused on neurohealth, has announced new partnerships with mental health advocates for National Depression Education and Awareness Month. The company’s NeuroStar® Therapy leads the non-invasive treatment for depression. The campaign, featuring Dr. Melissa Shepard, aims to educate patients and physicians on this breakthrough technology. Additionally, NeuroStar is sponsoring key events to raise awareness and promote mental health research. With over four million treatments delivered, NeuroStar remains committed to transforming lives through effective non-drug therapies.
Neuronetics (NASDAQ: STIM) has partnered with Zion Healing to become the exclusive supplier of TMS equipment for Zion's mental health clinics. This agreement aims to enhance patient access to NeuroStar® Advanced Therapy, a non-invasive treatment for depression. Robert Beatty, CEO of Zion Healing, emphasized the urgent need for mental health services, while Neuronetics' President, Keith J. Sullivan, highlighted the partnership's potential to expand treatment availability. NeuroStar has delivered over 4 million treatments, demonstrating its efficacy in adult patients with major depressive disorder.
Neuronetics, Inc. (NASDAQ: STIM) announced the launch of an enhanced website aimed at improving the user experience for patients seeking information on advanced depression treatments. Market research reveals that 67% of Major Depressive Disorder patients are dissatisfied with current treatments. The new site provides essential resources, including a physician locator tool and success stories, to empower patients and healthcare providers. With rising depression rates post-COVID-19, this initiative underscores Neuronetics' commitment to addressing unmet mental health needs.
Neuronetics (NASDAQ: STIM) has appointed Megan Rosengarten to its Board of Directors, expanding the board to eight members. Rosengarten brings over two decades of experience in medical technology, currently serving as President of Surgical Robotics at Medtronic. She previously held roles at Hologic, Covidien, and Johnson & Johnson. Her expertise in product development and marketing is expected to enhance Neuronetics' growth strategy for its NeuroStar Advanced Therapy for Mental Health, which is FDA-cleared for treating major depressive disorder. The company aims to increase awareness and adoption of this innovative therapy.
FAQ
What is the current stock price of Neuronetics (STIM)?
What is the market cap of Neuronetics (STIM)?
What does Neuronetics Inc. specialize in?
How does the NeuroStar Advanced Therapy System work?
What makes Neuronetics different from other medical device companies?
Who are the primary patients for NeuroStar therapy?
How does Neuronetics generate revenue?
What role does clinical research play in Neuronetics' strategy?
How does Neuronetics collaborate with healthcare providers?
